1 billion-level varieties three-fold to grab the market Heng Rui, Koren announced a price reduction!

Pharmaceutical network July 15th, the national collection, local collection, health insurance negotiations and other policies, the domestic drug market price changes greatly, and some products in the policy before and after the impact of the response, price slower prices, market shrinkage ..Under the policy market, china's pharmaceutical market side of the sea changes are under wayrecently, a large number of products actively apply for a price reductionOn July 10,, Jiangsu Province again issued an announcement on drug price adjustmentthis time involved in the price reduction of a total of 86 varieties, although the vast majority of products price reduction of no more than 20%, but there are three products from GSK, HengRui, Collon products fell by more than 50%01 into the HIV market bomb in this price adjustment, GSK's dothirave sodium tablets (commodity name: Tweekai) from 1980 yuan / bottle to 980 yuan / bottle, a reduction of more than 50%December 30, 2015, Tweede yuk et lurched in China to treat adults infected with human immunodeficiency virus (HIV) and children up to 12 years of age through a combination of other antiretroviral drugsapproved with a Child Adaptation Certificate in 2019the World Health Organization (WHO) updated in 2018's GUIDELINEs for AIDS Prevention and Treatment, recommended Dotiravir (DTG) as the first-line treatment of HIV and AIDS in adults and adolescentsas a second-generation integrative enzyme inhibitor, Tweeke was first approved by the U.SFDA in August 2013 for hiv-infected people treatment, less than three years into the Chinese market, at that time is relatively fastwas initially priced at 1980 yuan per bottle, lower than the surrounding countriesthe market of Tweekai, also opened a large number of new AIDS drugs in China, in 2018 GSK declared the Chinese mainland HIV treatment field's first complete treatment program single-chip compound preparation Zimeikai market, the same year Gilead's single tablet treatment drug Jiefukang also listed, 2019 Gilead's single-chip compound preparation Requirtovi was approved for market, Bhp vie is currently the world's highest sales of HIV anti-virus drugsbut it is worth noting that China's AIDS drug market has one characteristic: dual accesssince the implementation of the "four free one care" policy in 2003, China's hiv-diagnosed AIDS patients can be provided with free anti-viral drugsAccording to the National Free AIDS Antiviral Treatment Manual and the 2019 Medical Insurance Directory, a total of 8 drugs are included in the National Free Drug Use, and 20 AIDS drugs (including free medication) are included in the National Medical Insurancewhen Tweede launched in China in 2016, it also said it would work with the Chinese government to include it in the free-to-use list as soon as possible, but GSK has so far failed to achieve that goal because of its caution over new drugsof the new drugs approved in recent years, only Gilead's JieFukang through the 2019 health care negotiations into health insurance, and cut prices by more than 60% to 1290 yuan / bottle admission, patients in the retail channels can buy at this price, and after medical insurance reimbursement price is only two or three hundred yuan a bottle, for the free drug policy and in recent years approved new drugs, no doubt a bomb into the domestic marketaccording to the finishing of Southwest Securities, the current domestic anti-HIV new drugs, Tweekai sales of the largest, 2019 reached 24.4 million yuan, followed by cutting-edge biological approval in 2018 Ai Kening, GSK's Yu Meikai and Gilead's Jie Fukang 5.47 million and 3.83 million yuan, respectivelybut still dominate the domestic market are older imports and domestic generics, such as Abervey's Kreiss, Chengdu's Beit's Doubleletter and so onand global market, Between Bitowi and Jet-Fukang are already in the top twoas a single compound tablets, the company will largely affect free drugs including generic drugs and the market for new drugs listed in recent years, and GSK's Tweeke in the global sales growth, also choose to reduce prices for survival, and its other drug, YuMeikai also in the existing 2880 yuan / monthly pricing based on a certain period of time to buy a free one activity, actually lower the threshold of self-fundingalthough Gilead's products are reduced in price for health insurance, but because AIDS patients or carriers of the virus in the absence of resistance or side effects of the less likely to change drugs in the middle of the case, so the current other products in addition to solidified the original drug base, but also need to strive to cover the new patientsAnd for local companies that have been starring in anti-HIV drugs in recent years, price pressures will also rise sharply02 Hengrui and Koren glue, 1 billion market shrinkage and this time announced in Jiangsu Province, the highest price reduction of the two products are sodium bicarbonate Ringer injection, Hengrui 500 ml capacity of sodium bicarbonate Ringer injection, from 280 yuan to 98 yuan, a drop of 65%; Collum's same-standard products decreased from 238 yuan to 64 yuan, a decrease of up to 73%Sodium bicarbonate ringer injection is a compound electrolyte injection, used in the circulation of blood volume and inter-tissue fluid reduction (such as perioperative period, etc.), as a supplementary regulator of extracellular fluid, to correct metabolic acidosisits original research plant is Otsuka, Japan, in 2010 was approved for listing in JapanHengrui and Collum were approved in April and June 2019, respectively, but less than a year after the approval, on March 31 this year, Curran took the lead in Shaanxi active price reduction, bicarbonate of sodium-hydrogen-linked injection 500ml / bag of the product regulations from 238 yuan to 64 yuan, 1000 ml / bag of product regulations from 498.1 yuan to 108.8 yuanfollowed, on April 24, Hengrui also announced a price reduction in Shaanxi, 500ml /bag net price limit from 295 yuan to 98 yuan, a decrease of 66.78 percentsubsequently, the two enterprises in Heilongjiang, Beijing, Guangxi, Henan, Jiangsu and other provinces have been simultaneous lying down pricesThe Monitta Institute believes that the market space for sodium bicarbonate ringer injections is more than 1 billion, and it is also an upgrade product of Henri potassium magnesium calcium glucose injection, which has the potential to replace its market in the futuresales of Hengrui sodium potassium magnesium calcium glucose injections in 2018 will be about 28 million bags, with annual sales of 2.8 million bags if sodium bicarbonate is replaced by one-tenth of its market but it is worth noting that the above-mentioned forecast of market space is based on the price of sodium bicarbonate ringer at 350 yuan / bag or so, and now HengRui and Collon have hit a price of about 3 fold, the market space of this product will also shrink, 1 billion market can be reached, a question mark , this variety also has the original research Big Yu Pharmaceuticals, U.S Dakang Jiale Pharmaceuticals, Hubei Dori Pharmaceuticals and Xi'an Bandung Pharmaceuticals declared production, and Wuhan Pharmaceutical Valley Bioengineering Co., Ltd was approved clinical with only two listings, Hengrui and Colum cut prices by nearly 80 per cent at the same time, putting more price pressure on their competitors and helping both to seize the market with a batch of varieties into the national collection, as well as provincial, local-level band procurement, drug prices fell into the main theme of the past few years, but each time the price reduction is more than imagined bicarbonate of bicarbonate ringer injection may be a microcosm of the impact of the collection, although not yet included in the collection, but with the increasing competition, large varieties into the collection of more and more likely, and these two enterprises choose the same "first start for the strong."